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The role of the unusual threonine
string in the conversion of prion
protein
Romany Abskharon1,2, Fei Wang1, Kayla J. Vander Stel1, Kumar Sinniah3 & Jiyan Ma1
The conversion of normal prion protein (PrP) into pathogenic PrP conformers is central to prion disease,
but the mechanism remains unclear. The α-helix 2 of PrP contains a string of four threonines, which is
unusual due to the high propensity of threonine to form β-sheets. This structural feature was proposed
as the basis for initiating PrP conversion, but experimental results have been conflicting. We studied
the role of the threonine string on PrP conversion by analyzing mouse Prnpa and Prnpb polymorphism
that contains a polymorphic residue at the beginning of the threonine string, and PrP mutants in
which threonine 191 was replaced by valine, alanine, or proline. The PMCA (protein misfolding cyclic
amplification) assay was able to recapitulate the in vivo transmission barrier between PrPa and PrPb.
Relative to PMCA, the amyloid fibril growth assay is less restrictive, but it did reflect certain properties
of in vivo prion transmission. Our results suggest a plausible theory explaining the apparently
contradictory results in the role of the threonine string in PrP conversion and provide novel insights into
the complicated relationship among PrP stability, seeded conformational change, and prion structure,
which is critical for understanding the molecular basis of prion infectivity.
Transmissible spongiform encephalopathies (TSEs), or prion diseases, are a group of fatal neurodegenerative
diseases that includes Creutzfeldt-Jakob disease (CJD) in humans, scrapie in sheep and goats, bovine spongiform
encephalopathy (BSE) in cattle, and chronic wasting disease (CWD) in cervids1. The prion hypothesis posits that
the conversion of normal host-encoded prion protein (PrP) is central to the pathogenesis of these diseases2,3. The
normal PrP isoform (PrPC) is a cell surface glycoprotein that is soluble, protease-sensitive, and rich in α-helices.
During the disease, some PrPs convert to the aberrantly folded isoform (PrPSc), which is aggregated, resistant to
protease digestion, and rich in β-sheets3–5. The pathogenic PrPSc is able to seed a conformational change of normal PrPC into PrPSc, resulting in PrPSc accumulation and neurodegeneration. Decades of research have provided
compelling evidence supporting the hypothesis6,7.
The normal isoform, PrPC, contains a long unfolded N-terminal region and a C-terminal globular domain
consisting of three α-helices and two short anti-parallel β-strands8–11. Although small changes in the amino acid
sequence do not significantly alter the overall structure of PrPC9,10, they can severely alter prion transmissibility12–16.
PrP sequence variations in different species create strong barriers against inter-species prion transmission17,18.
Within the same species, PrP polymorphisms also greatly influence the susceptibility to intra-species prion transmission12,15,19,20. A classic example of an intra-species barrier is the mouse PrP polymorphism of allele a (Prnpa;
Leu at residue 108 and Thr at residue 189) and allele b (Prnpb; Phe at residue 108 and Val at residue 189), which
drastically alter the length of the incubation period of prion disease12,20,21. Elegant studies with knock-in mice
revealed that the most efficient prion transmission requires both residues in the host PrP to match those of the
inoculum PrP20. While both residues 108 and 189 affect the incubation time, residue 189 plays a major role in
determining the efficiency of prion transmission20.
Residue 189 is within the highly conserved string of 4 threonines located at the C-terminus of α-helix 2 of PrP
(Fig. 1)22. Because threonine tends to form β-sheet structures23, such a sequence of β-sheet-prone threonines in
a helix is highly unusual. This local instability has been proposed as the underlying structural basis for initiating
the PrPC-to-PrPSc conversion24. Consistent with this hypothesis, the C-terminus of α-helix 2 has been found to
be unstable25,26, and the peptide corresponding to helix 2 is able to form amyloid fibrils that can act as seeds for
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Figure 1. Schematic representation of murine PrP. PrP consists of a long N-terminal disordered region and a
C-terminus that has three α-helices and two anti-parallel β-strands. The sequences of PrPa, PrPb, two derivative
mutants (L108F and T189V), and three residue-191 mutants are shown; mutations are indicated in red.

full-length wild-type PrP27. Replacing threonines with α-helix-prone alanines stabilizes the PrPC structure and
prevents in vitro PrP aggregation28. A thermodynamic study of the α-helix 2 peptide showed that the free energy
separating the α-helix and β-sheet conformations of this peptide is very small, indicating that the structural
behavior of this peptide is likely determined by the environment29. Indeed, compounds binding to this region
have been shown to prevent PrP conversion and increase the survival of diseased animals30–32.
Interestingly, the insertion of extra amino acids in the C-terminus of α-helix 2 does not affect the ability of
mutant ovine PrPs to convert to the infectious PrPSc conformation22. Further, a comprehensive mutagenesis study
of mouse PrP showed that individually replacing the amino acids in the C-terminus of α-helix 2 with any other
amino acid does not significantly influence the formation of infectious prions in scrapie-infected N2a cells33.
Very recently, Munoz-Montestino reported that deleting 4 or 5 amino acids in this region (including all four
threonines) does not affect the conversion of ovine PrP to infectious prions in RK13 cells34. These data apparently
contradict the observations from prion transmission studies in Prnpb knock-in mice, which showed that the threonine 189 (mouse numbering) significantly affects disease incubation times20.
The above studies were performed on cultured cells or living animals, and multiple factors might alter the
efficiency of PrP conversion in these complicated systems (such as cell metabolic state, PrP presentation on the
cell surface, the presence of multiple cofactors, etc.). Therefore, we chose two relatively simple in vitro assays that
recapitulate many characteristics of PrPC-to-PrPSc conversion to study the influence of the threonine string in
prion conversion. The first is protein misfolding cyclic amplification (PMCA), which consists of successive sonication and incubation steps35. We previously showed that this technique can convert bacterially expressed recombinant PrP (recPrP) into aggregated and proteinase K (PK)-resistant conformer in the presence of cofactors36,37.
This conformational change produces recPrion, the pathogenic conformer of recPrP, that causes bona fide prion
disease in wild-type mice with pathological properties identical to those of naturally occurring prions36,38. In
addition to PMCA, we also used a denaturant-induced recPrP amyloid fibril formation assay39–41, which is commonly used to model PrP conversion.
Using these two assays, we compared recombinant PrPa and PrPb, two derivatives of PrPa bearing either Phe at
residue 108 (108 F) or Val at residue 189 (189 V), and three PrPa mutants that replace Thr 191 with either valine,
alanine, or proline. Our results offer new insights into the conversion of PrP into an infectious prion.

Results

PrPb polymorphism compromises recPrP conversion by PMCA.

The presence of Phe 108 and Val
189 in PrPb creates a strong barrier to the transmission of PrPa-based prion strains20,42. The recPrion was generated de novo by PMCA from recPrPa protein36 and it has been propagated with recPrPa for years. To determine
whether there is a transmission barrier between recPrion and recPrPb, we propagated recPrion with recPrPb or
with the PrPa-derived mutants recPrPL108F and recPrPT189V. PMCA was carried out as described previously38,43;
the PMCA substrate consisted of recPrP plus two cofactors, synthetic POPG and total RNA isolated from normal mouse liver38,43. For each recPrP variant, PMCA was carried out for six rounds, and the generation of the
C-terminal PK-resistant PrP band at round 6 was considered a successful propagation. As a positive control,
recPrPa was successfully propagated (Fig. 2 and Table 1). In contrast, PrPb and the two derivative mutants failed to
propagate in all 20 trials (Fig. 2 and Table 1). These data suggested that, similar to the barrier observed in animal
study20, there is a barrier for propagating recPrPa-adapted recPrion to recPrPb and that both polymorphic residues 108 and 189 contribute to the barrier.

PrPb polymorphism at residues 108 and 189 differently affect recPrP amyloid fibril growth.

Next, we analyzed the influence of PrPb polymorphism on PrP conversion with the less stringent but commonly
used in vitro recPrP amyloid fibril growth assay39. In unseeded reactions, the amyloid fibril formation by recPrP
was highly variable (Fig. 3a). Within the 96-h experiment, 4 out of 5 recPrPa replicates formed amyloid fibrils
de novo after a lag time of about 56 h. For recPrPb, only 1 out of 5 replicates formed amyloid fibrils de novo after
Scientific Reports | 6:38877 | DOI: 10.1038/srep38877
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Figure 2. PMCA propagation of recPrion. Recombinant PrPa, PrPb, PrPL108F, or PrPT189V was used as the
substrate for PMCA. Each PMCA reaction was carried out for 6 rounds and PMCA products were digested with
50 μg/mL PK at 37 °C for 30 min. PrP was detected by immunoblot analysis with POM1 anti-PrP antibody55. “C”
indicates undigested recPrP as a control. The original immunoblot images are in the Supplementary Figure S3.

Figure 3. Amyloid fibril growth with recombinant PrPa, PrPb, PrPL108F, or PrPT189V. Thioflavin-T (ThT)
kinetics of recombinant PrPa, PrPb, and two derivative mutants (L108F or T189V) in the absence (a) or in the
presence (b) of seeds. The seeds used were pre-formed recPrPa amyloid fibrils. Shaded areas are error bars,
which indicate standard deviation.

PMCA Successful PMCA/
total No. of PMCA

Amyloid fibril
De novo growth

Amyloid fibril
Seeded growth

Tm (˚C)
(± SD)

PrPa

20/20

+++

+++

78.8 ±  3.5

PrPb

0/20

+

+

74.1 ±  2.2

L108F*

0/20

+++

+++

69.6 ±  2.1

T189V*

0/20

+

+

69.6 ±  1.6

T191A*

5/20

+++

+++

70.3 ±  1.1

T191V*

12/20

+++

+++

69.4 ±  2.2

T191P*

0/20

+

+++

74.3 ±  0.9

Protein

Table 1. Properties of rPrP variants. *The PrP variants were generated on rPrPa background. Tm is the
melting temperature of PrP variants. SD represents standard deviation.

a lag time of about 79 h, and none of the other 4 recPrPb replicates formed fibrils within the 96-h experiment
(Fig. 3a). These results were consistent with a previous report showing that recPrPb has a reduced capability to
form amyloid fibrils44.
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Figure 4. PMCA propagation of recPrion with recombinant PrPT191A, PrPT191V, or PrPT191P as substrate.
Each reaction was run for 6 rounds and PMCA products were digested with 50 μg/mL PK at 37 °C for 30 min.
PrP was detected by immunoblot analysis with POM1 anti-PrP antibody. “C” indicates undigested recPrP as a
control. The original immunoblot images are in the Supplementary Figure S3.

Surprisingly, when the two PrPa-derived mutants recPrPL108F and recPrPT189V were tested, they behaved differently. Within the 96-h experiment, 4 out of 5 recPrPL108F replicates formed amyloid fibrils de novo with a lag time
similar to that of recPrPa (Fig. 3a). The recPrPT189V however, behaved similar to recPrPb (Fig. 3a), that is, only 2
out 5 recPrPT189V replicates formed amyloid fibril de novo within 96 h, and the average lag phase was around 91 h.
The same trend was observed in seeded reactions, in which all four recPrPs were seeded with the same recPrPa
fibril seed and amyloid fibril growth was detected in all samples with less variation. The recPrPL108F behaved like
recPrPa, both showing a rapid growth of amyloid fibrils (Fig. 3b). In contrast, recPrPT189V and recPrPb amyloid
fibril growth had a longer lag phase, and the intensity of ThT fluorescence signal was much lower (Fig. 3b). Since
these reactions were monitored at the same time, in the same plate, and under identical condition, the difference
in amyloid fibril growth is likely resulted from the different amino acid sequences of recPrP.
Overall, these results supported the idea that the recPrPb protein has a reduced capability to form amyloid
fibrils, which is largely due to the influence of residue 189 of PrP. These findings are consistent with the observations in animal studies that residue 189 is the major determinant for the transmission barrier between PrPa and
PrPb. However, the amyloid fibril growth results regarding residue 108 were different from in vivo findings20.

The influence of mutations at residue 191 on recPrP conversion. Because residue 189 has a larger
influence on the PrPa/PrPb transmission barrier and it is at the beginning of the 4-threonine string of α-helix 2,
it is reasonable to ask if changing another threonine residue within that string would have similar effects. Thus,
we mutated Thr-191 in recPrPa to Val to mimic the recPrPT189V change in recPrPb. We also mutated Thr-191 to
α-helix-prone Ala or to the secondary structure breaker Pro. All three mutants were expressed, purified, and
subject to PMCA.
Unlike recPrPT189V, recPrPT191V was able to propagate recPrion by PMCA, but the efficiency was lower (about 60%)
and the PK-resistant band at the 6th round was generally weaker than that of recPrPa (Fig. 4 and Table 1). The
recPrPT191A mutant had an even lower efficiency, only around 25% of reactions completed six rounds of propagation, and the PK-resistant band was also weaker than that of recPrPa (Fig. 4 and Table 1). On replacing Thr 191
with Pro, none of the 20 trials yielded successful propagation (Fig. 4 and Table 1). Thus, relative to Thr-189, Thr191 is more tolerant to amino acid replacement (with the exception of Pro): both Val and Ala at this position can
be tolerated but with less-efficient recPrion propagation by PMCA.
All residue-191 mutants were assayed for amyloid fibril growth. In unseeded reactions, 4 our 5 recPrPT191A or
recPrPT191V were able to form fibrils de novo, which were similar to wild-type recPrPa (4 out 5 replicates formed
amyloid fibrils) except for the longer lag phases (Fig. 5a). For recPrPT191P however, only 1 out of 5 replicates
formed fibril de novo within the 96-h experimental period, and the lag phase was 94 h (Fig. 5a). When fibril
growth was seeded with recPrPa fibril seed, all three residue-191 variants grew amyloid fibrils robustly (Fig. 5b).
Thus, except for the reduced ability of recPrPT191P to form amyloid fibrils de novo, no significant difference in
amyloid fibril growth was found when Thr-191 was replaced with Val, Ala, or Pro.
Detecting prion infectivity of converted recPrP variants using cell infection assay.

The Elispot
plate–based cell infection assay is a sensitive and quantitative prion infectivity measure45,46. We used CAD5 cells,
a clonally selected cell line that is susceptible to infection by most mouse prion strains45,46, to test PMCA products
for two purposes. First, we wanted to determine whether the in vitro converted recPrP variants were infective.

Scientific Reports | 6:38877 | DOI: 10.1038/srep38877
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Figure 5. Amyloid fibril growth with recombinant PrPT191A, PrPT191V, or PrPT191P. ThT kinetics of
recombinant PrPa, PrPT191A, PrPT191V, or PrPT191P in the absence (a) or presence (b) of seeds (pre-formed recPrPa
amyloid fibrils). Shaded areas are error bars, which indicate standard deviation.

Figure 6. Elispot cell culture assay of prion infectivity. CAD5 cells were infected with serial 10-fold dilutions
of each PMCA product as indicated. Elispot assay was performed by filtering 20,000 third-passage cells onto the
membranes of Elispot plates, and the proportion of cells contained PK-resistant PrP was identified by enzymelinked immunosorbent assay (ELISA).
Second, because the endogenous PrP in CAD5 cells is wild-type PrPa, using converted recPrP variants to infect
the cells would allow us to evaluate the effect of amino acid mismatch on PrP conversion.
The round-6 PMCA products were used for the assay. As shown in Fig. 6, no infectivity was detected in
the recPrP variants that did not produce a detectable C-terminal PK-resistant band, i.e., recPrP b, recPrPL108F,
recPrPT189V, and recPrPT191P (Fig. 6). This result supports the notion that PrP conformation is the main determinant of prion infectivity. The three recPrP variants that generated the PK-resistant conformer at round 6 all had
prion infectivity (Fig. 6). Although the PK-resistant bands of recPrPT191V and recPrPT191A were much weaker than
that of recPrPa (Figs 2 and 4), the infectivity of recPrPT191V was comparable to that of wild-type recPrPa and the
infectivity of T191A mutant was lower by about one order of magnitude. Nonetheless, the undiluted samples of
recPrPa, recPrPT191V, and recPrPT191A produced similar numbers of cells carrying PK-resistant PrPSc (Fig. 6), suggesting that the amino acid mismatch at 191 did not significantly affect the seeded conversion process.

Thermal stability of recPrP variants.

The sequence of four threonines at the C-terminus of α-helix 2 is
unstable, which has led to it being proposed as a possible initiator of PrP conversion24–26. To determine the change
in thermal stability among different recPrP variants generated in this study, we used a CPM (7-diethylamino-3(4-maleimidophenyl)-4-methylcoumarin) thermal stability assay47,48. Among all the recPrPs, recPrPa had the
highest melting temperature (Tm = 78.8 °C) (Fig. 7, Table 1). The Tm for recPrPb was 74.1 °C, suggesting it is less
thermally stable than recPrPa. All single amino acid variants except for recPrPT191P had melting temperatures
around 70 °C, and recPrPT191A had the highest Tm among this group (70.3 °C), consistent with the idea that the
α-helix prone alanine stabilizes the helical structure of recPrP. Interestingly, recPrPT191P had the highest melting
temperature (74.3 °C) among all recPrP variants, suggesting that this recPrP, with a shortened α-helix 2, is quite
Scientific Reports | 6:38877 | DOI: 10.1038/srep38877
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Figure 7. Thermal stability curves of recPrPs. The recPrP in deionized water (2 mg/mL) was used to obtain
the thermal stability profiles. Melting temperatures (Tm) were determined by fitting the curves to a Boltzmann
sigmoidal equation using GraphPad Prism (version 6).
stable; this result is consistent with a recent report34. Importantly, there was no correlation between thermal stability and PrP conversion, either by PMCA or by amyloid fibril growth assay.

Discussion

In this study, we investigated the influence of the string of four threonines on PrP conversion by using two in vitro
PrP conversion assays. The PMCA assay showed that the transmission barrier between murine PrPa and PrPb can
be recapitulated in recPrion propagation and that both residues 108 and 189 contribute to the barrier. The amyloid fibril growth assay revealed a strong influence of residue 189 on fibril growth, but residue 108 had little effect.
Moreover, our results also showed a position effect in the threonine string. When Thr-191 was mutated to Val or
Ala, the mutants converted to the infectious prion conformation with a reduced efficiency. But when Thr-191 was
mutated to Pro, it could not be converted by PMCA, suggesting that this residue is likely to be part of the β-sheet
core, but not the loop region of in the final infectious conformation. Finally, we have shown that the variations
in thermal stability caused by these PrP polymorphisms or mutations do not correlate with the ability of these
recPrP to convert to either amyloid fibrils or infectious prions.
The lack of correlation between PrP thermal stability and convertibility is not particularly surprising. The
instability of PrP will lead to misfolding or aggregation, but infectious prion conformations and/or amyloid fibril
structures are ordered protein aggregates with defined structures, which require the normal PrP not only to
unfold, but also to gain the defined structure of infectious prions or amyloid fibrils. Since unfolded PrP does not
spontaneously convert to ordered aggregates, simply increasing the instability of PrP will increase PrP misfolding,
but not necessarily result in increased production of infectious prions or amyloid fibrils.
The PrPa/PrPb transmission barrier was originally identified through genetic analyses of prion disease susceptibility in mouse strains49,50 and elegantly dissected by using knock-in mouse technology20,21. Here we used
PMCA to show that the difference of two amino acids between recPrPa and recPrPb created a barrier to propagating recPrPa-adapted recPrion, and both residues contributed to this barrier. Note that by changing the PMCA
parameters, it is possible to adapt the prion propagation to various types of prions, as illustrated by propagating
mouse prion to hamster PrPC via PMCA51. In order to study the PrPa/PrPb transmission barrier, we did not make
any adjustment and used PMCA parameters that propagate recPrion with recPrPa to test all recPrP variants,
which allowed us to detect differences in transmission efficiency. The compromised PMCA propagation with
recPrPb or the derivative mutants recPrPL108F and recPrPT189V was consistent with in vivo results20.
Relative to PMCA, the amyloid fibril growth assay is less restrictive, and all recPrP variants grew amyloid
fibrils (Suppl. Fig. 1, Table 1). Similar to the report by Cortez et al.44, we found that recPrPb was less efficient in
forming amyloid fibrils. Unexpectedly, recPrPL108F behaved similarly to recPrPa in both unseeded and seeded
reactions (Figs 3 and 5), suggesting that the properties of recPrPb in amyloid fibril growth are largely determined
by residue 189. This finding is consistent with observations from animal study20, but the lack of influence of residue 108 is not. Unlike PMCA products, none of the amyloid fibrils could infect cultured CAD5 cells (data not
shown) or seed the PMCA reaction (Suppl. Fig. 2). These observations suggest that the amyloid fibril growth assay
is a less faithful PrP-conversion assay than PMCA. Notably, it has been suggested that recPrP has the freedom to
oligomerize to a large number of assemblies in the presence of 2 M GuHCl (a condition for growing PrP amyloid
fibrils) and recPrP amyloid fibrils are able to adapt to the structure that is most suitable for the buffer conditions44,52. Thus, the misfolded recPrP has more freedom to adopt various structures under amyloid fibril growth
Scientific Reports | 6:38877 | DOI: 10.1038/srep38877
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condition, which may account for the less faithfulness by the amyloid fibril growth assay. Nonetheless, our finding
that residue 189 is the major determinant of the fibril-growing property of recPrPb reveals that the amyloid fibril
growth assay does recapitulate certain aspects of in vivo PrP conversion.
Thr-189 is at the beginning of the unusual four-threonine sequence in the α-helix 2 of PrP (Fig. 1), and the
role of this string in PrP conversion is controversial22,24–26,33,34. In our PMCA study, all variants in this string had
a reduced capability to form infectious prions, which could be due to the influence on three aspects of PrP conversion: (1) the seeding process, (2) the PrP conformational change, and (3) the final prion structure. Given that
recPrion formed by recPrPT191V or recPrPT191A efficiently seeds wild-type PrP in CAD5 cells (Fig. 6), the amino
acid mismatch between recPrP variants and wild-type PrP does not appear to significantly affect the seeding
process. Because a single amino acid change is unlikely to alter the protein conformational change process, the
most plausible explanation is that the threonine string forms part of the β-sheeted core of recPrion. This theory is
consistent with our observation that replacing Thr-191 with Pro, a secondary structure breaker, strongly inhibits
the propagation of recPrion by PMCA.
Although our data is consistent with the threonine string being a part of the β-sheeted core of recPrion,
it does not suggest that this sequence is an obligatory part of the core in all prion strains. The finding by
Munoz-Montesino et al. that deleting all four threonines does not affect the conversion of ovine PrP in RK13
cells34 indicates that this stretch is in the non-essential part in certain prion strains. Removing the threonine
string may reduce the restraint of the final infectious prion structure of some prion strains, which would allow
the PrP to better accommodate the incoming prion structure and propagate prion structures that it normally
has difficulty propagating. This would explain the more efficient propagation of ovine PrP-adapted CJD strains
by threonine deletion mutant34. Overall, our theory that the threonine string constitutes the β-sheeted core in
certain prion strains, but is in the non-essential region in other strains explains the seemingly conflicting results,
particularly the strong influence of residue 189 on prion transmission20 and the efficient prion formation by the
threonine deletion mutant34.
It is important to note that the recPrion was formed de novo in a test tube with recPrP36, which might be different from native prions formed in animals. The PMCA and amyloid fibril growth are both in vitro assays, which
may only capture certain aspects of the in vivo prion propagation process. Notwithstanding the limitations, these
in vitro assays offer relatively pure systems allowing us to assess the direct effects of these amino acids on PrP
conversion, which is difficult to achieve using in vivo systems. Moreover, the relevance of our findings to in vivo
prion biology is supported by the facts that the recPrion causes bona fida prion disease in wild-type animals36,38.
Further, our PMCA results are fully consistent, and our findings from amyloid fibril growth assay are partially
consistent, with the results of in vivo prion transmission in knock-in mice20.
In summary, we compared the PMCA propagation of recPrion with the amyloid fibril growth assay; analyzed
the complicated relationships among PrP thermal stability, PrP conversion, and prion infectivity, which have
resulted in novel insights into the role of the threonine string in forming infectious prions. Confirmation that
the threonine string can be part of the β-sheeted core or non-essential region in different prion strains may offer
a novel view of the structural differences among various strains and help elucidate the molecular structure of
infectious prions.

Methods

Site-directed mutagenesis. The mutant variants of the mouse PrP were generated from pPROEX HTb
vector containing mouse PrP23–230 using the QuikChange site-directed mutagenesis kit (Stratagene). The primers are listed in the online supplementary information, which were synthesized by Integrated DNA Technologies,
Inc. (IDT). All mutations were confirmed by DNA sequencing.
Expression and purification of recPrPs.

All recPrP proteins were expressed in E. coli BL21 (DE3) and
purified according to a previously reported protocol53 with minor modifications. Briefly, inclusion bodies were
collected (15,000 ×  g, 30 min, 4 °C), resuspended in 6 M Guanidine hydrochloride (GuHCl), 10 mM Tris-HCl,
100 mM Na-PO4 buffer, 10 mM β-mercaptoethanol (βME), pH 8.0, sonicated on ice until completely solubilized,
and applied to a Ni-NTA column (Qiagen). The recPrP was refolded on the column by running a GuHCl gradient
(from 6 M GuHCl, 10 mM Tris-HCl, 10 mM βME, pH 8.0 to 10 mM Tris-HCl, 100 mM Na-PO4 buffer, pH 8.0) at
1 mL/min. After wash, recPrP was eluted with 10 mM Tris-HCl, 100 mM Na-PO4 buffer, and 500 mM imidazole,
pH 5.8. All eluted fractions were combined and dialyzed using 7,000 MWCO, SnakeSkinTM Dialysis Tubing
(Thermo Scientific) for 1.5 h against 10 mM Na-PO4 buffer, pH 5.8, and then dialyzed overnight against deionized
water. Protein samples were lyophilized (FreeZone 4.5, LABCONCO) and stored at −80 °C for further use.

Protein misfolding cyclic amplification (PMCA).

The PMCA reaction was carried out as previously
described43,54. Each PMCA round consisted of 48 cycles of sonication (0.5 min) and incubation (29.5 min), and
1/10 of the reaction mixture was transferred to a fresh substrate mixture to start a new round.

Amyloid fibril formation assay. For amyloid fibril growth, 0.5 mg/mL of recPrP was incubated in 2 M
GuHCl, 100 mM K-PO4 buffer, pH 6.5, and 20 μM thioflavin T (ThT). The reaction volume was 200 μL per well
in 96-well plates (Corning, Lot No. 065514030). In the seeded reaction, seeding was achieved by adding 1 μL of
mouse recPrP fibrils (0.5 mg/mL) to each well. The plate was incubated at 37 °C with continuous shaking on a
mcrioplate reader (SYNERGY2, BioTek). The fibril kinetics was monitored by measuring ThT fluorescence intensity every 15 min using 440-nm excitation and 480-nm emission. The amyloid-formation kinetics was calculated
from five replicates using GraphPad Prism (GraphPad Software, Inc.).
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The enzyme-linked immunospot (Elispot) cell infection assay. The Elispot cell infection assay was
adapted from previous studies45,46 with minor modifications. Briefly, 200 μL of PMCA products at round 6 were
collected and centrifuged at 100,000 × g, 4 °C for 1 hour and the pellets were washed twice, followed by centrifugation at 100,000 × g, 4 °C for 1 hour after each wash. After the final wash, the pellets were resuspended in 200 μL
of CAD5 growth media (OPTI-MEM, 5% BGS and 1% penicillin and streptomycin) and sonicated for 30 seconds
with 50% output (Misonic Sonicator XL2020). Each sample was serially diluted 10, 100, and 1,000 times and 60 μL
of undiluted and diluted samples were used to infect CAD5 cells. After two 1:10 splits, 20,000 CAD5 cells/well
were transferred to the Millipore 96-well Elispot plates (MSIPN4W) and subjected to the Elispot assay45,46. The
images were taken by S6 Micro Analyzer (CTL Analyzers, LLC) and processed by the ImmunoSpot software
(CTL Analyzers, LLC). The graph was generated using GraphPad Prism (GraphPad Software, Inc.).
Thermal unfolding using CPM fluorescence dye.

The thermal stability assay was performed as previously described48. Briefly, 4 mg of 7-diethylamino-3-(4-maleimidophenyl)-4-methylcoumarin (CPM) (Sigma)
was dissolved in 1 mL of DMSO. The solution was diluted 20-fold with water to make a working solution, which
was kept on ice during the experiment. Diluted dye (40 μL) was mixed with 480 μL of 2 mg/mL recPrP and used
immediately while protected from light to reduce photobleaching. The thermal denaturation assay was performed in a total volume of 130 μL of reaction mixture, and the mixture was transferred to a sub-micro quartz
fluorometer cuvette and heated at a rate of 2 °C/min in a Cary Eclipse fluorescence spectrophotometer (Agilent
Technologies). The fluorescence signal was monitored as the temperature increased (excitation 387 nm, emission
463 nm). The assay was performed over the temperature range of 20–95 °C. Data were fitted using the GraphPad
Prism program (GraphPad Software, Inc.), and the melting temperature (Tm) was calculated from the Boltzmann
sigmoidal equation. Each experiment’s calculations were based on an average of 4 replicates.
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